Bruce Coate, MPH

Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

Depression occurs in ~50% of Parkinson’s disease (PD) patients, increases in severity as the disease progresses, and is associated with increased morbidity. We are assessing use of pimava...

Daryl DeKarske , MPH;

Bruce Coate , MPH;

James C. Norton , PhD;

Michael Guskey , PharmD;

Gustavo Alva , MD, DFAAPA;

Jason Aldred , MD, FAAN;

Marc Cantillon , MD;

11/22/2019

Depression in Parkinson`s Disease: Investigations of Pimavanserin, a Selective 5-HT2A Receptor Antagonist/Inverse Agonist

Depression occurs in 30–50% of Parkinson’s disease (PD) patients, yet no drugs are approved specifically to treat PD patients with depressive symptoms. Few clinical studies have been cond...

Rene Nunez , MD;

Maurizio Fava , MD, PhD;

Daryl DeKarske , MPH;

Lori Jacobi , BA;

Bruce Coate , MPH;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

10/08/2020

A Post Hoc Analysis Evaluating the Impact of a Reduction in Psychosis on the Severity of Agitation and Aggression in Patients With Alzheimer’s Disease

This post hoc analysis evaluates whether improvement in hallucinations and delusions during pimavanserin (PIM) treatment among Alzheimer’s dementia (AD) patients with psychosis leads to i...

Bruce Coate , MPH;

Michael Guskey , PharmD;

Srdjan Stankovic , MD, MSPH;

Clive Ballard , MBChB;

11/22/2019